Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Accumulating evidence indicates that immunotherapy helped to improve the survival and quality-of-life of patients with lung adenocarcinoma (LUAD) or lung squamous cell carcinoma (LUSC) besides chemotherapy and gene targeting treatment. This study aimed to develop immune-related gene signatures in LU...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Na Li, Jiahong Wang, Xianquan Zhan
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	lung cancer tumor microenvironment immune-related gene signature clinical characteristics tumor mutation burden Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/5043de7eff614eebada5e7504d27f9b1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5043de7eff614eebada5e7504d27f9b1
record_format	dspace
spelling	oai:doaj.org-article:5043de7eff614eebada5e7504d27f9b12021-11-30T12:04:56ZIdentification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma1664-322410.3389/fimmu.2021.752643https://doaj.org/article/5043de7eff614eebada5e7504d27f9b12021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.752643/fullhttps://doaj.org/toc/1664-3224Accumulating evidence indicates that immunotherapy helped to improve the survival and quality-of-life of patients with lung adenocarcinoma (LUAD) or lung squamous cell carcinoma (LUSC) besides chemotherapy and gene targeting treatment. This study aimed to develop immune-related gene signatures in LUAD and LUSC subtypes, respectively. LUAD and LUSC samples were divided into high- and low-abundance groups of immune cell infiltration (Immunity_H and Immunity_L) based on the abundance of immune cell infiltrations. The distribution of immune cells was significantly different between the high- and low-immunity subtypes in LUAD and LUSC samples. The differentially expressed genes (DEGs) between those two groups in LUAD and LUSC contain some key immune-related genes, such as PDL1, PD1, CTLA-4, and HLA families. The DEGs were enriched in multiple immune-related pathways. Furthermore, the seven-immune-related-gene-signature (CD1B, CHRNA6, CLEC12B, CLEC17A, CLNK, INHA, and SLC14A2) prognostic model-based high- and low-risk groups were significantly associated with LUAD overall survival and clinical characteristics. The eight-immune-related-gene-signature (C4BPB, FCAMR, GRAPL, MAP1LC3C, MGC2889, TRIM55, UGT1A1, and VIPR2) prognostic model-based high- and low-risk groups were significantly associated with LUSC overall survival and clinical characteristics. The prognostic models were tested as good ones by receiver operating characteristic, principal component analysis, univariate and multivariate analysis, and nomogram. The verifications of these two immune-related-gene-signature prognostic models showed consistency in the train and test cohorts of LUAD and LUSC. In addition, patients with LUAD in the low-risk group responded better to immunotherapy than those in the high-risk group. This study revealed two reliable immune-related-gene-signature models that were significantly associated with prognosis and tumor microenvironment cell infiltration in LUAD and LUSC, respectively. Evaluation of the integrated characterization of multiple immune-related genes and pathways could help to predict the response to immunotherapy and monitor immunotherapy strategies.Na LiNa LiJiahong WangXianquan ZhanXianquan ZhanXianquan ZhanFrontiers Media S.A.articlelung cancertumor microenvironmentimmune-related gene signatureclinical characteristicstumor mutation burdenImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung cancer tumor microenvironment immune-related gene signature clinical characteristics tumor mutation burden Immunologic diseases. Allergy RC581-607
spellingShingle	lung cancer tumor microenvironment immune-related gene signature clinical characteristics tumor mutation burden Immunologic diseases. Allergy RC581-607 Na Li Na Li Jiahong Wang Xianquan Zhan Xianquan Zhan Xianquan Zhan Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
description	Accumulating evidence indicates that immunotherapy helped to improve the survival and quality-of-life of patients with lung adenocarcinoma (LUAD) or lung squamous cell carcinoma (LUSC) besides chemotherapy and gene targeting treatment. This study aimed to develop immune-related gene signatures in LUAD and LUSC subtypes, respectively. LUAD and LUSC samples were divided into high- and low-abundance groups of immune cell infiltration (Immunity_H and Immunity_L) based on the abundance of immune cell infiltrations. The distribution of immune cells was significantly different between the high- and low-immunity subtypes in LUAD and LUSC samples. The differentially expressed genes (DEGs) between those two groups in LUAD and LUSC contain some key immune-related genes, such as PDL1, PD1, CTLA-4, and HLA families. The DEGs were enriched in multiple immune-related pathways. Furthermore, the seven-immune-related-gene-signature (CD1B, CHRNA6, CLEC12B, CLEC17A, CLNK, INHA, and SLC14A2) prognostic model-based high- and low-risk groups were significantly associated with LUAD overall survival and clinical characteristics. The eight-immune-related-gene-signature (C4BPB, FCAMR, GRAPL, MAP1LC3C, MGC2889, TRIM55, UGT1A1, and VIPR2) prognostic model-based high- and low-risk groups were significantly associated with LUSC overall survival and clinical characteristics. The prognostic models were tested as good ones by receiver operating characteristic, principal component analysis, univariate and multivariate analysis, and nomogram. The verifications of these two immune-related-gene-signature prognostic models showed consistency in the train and test cohorts of LUAD and LUSC. In addition, patients with LUAD in the low-risk group responded better to immunotherapy than those in the high-risk group. This study revealed two reliable immune-related-gene-signature models that were significantly associated with prognosis and tumor microenvironment cell infiltration in LUAD and LUSC, respectively. Evaluation of the integrated characterization of multiple immune-related genes and pathways could help to predict the response to immunotherapy and monitor immunotherapy strategies.
format	article
author	Na Li Na Li Jiahong Wang Xianquan Zhan Xianquan Zhan Xianquan Zhan
author_facet	Na Li Na Li Jiahong Wang Xianquan Zhan Xianquan Zhan Xianquan Zhan
author_sort	Na Li
title	Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
title_short	Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
title_full	Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
title_fullStr	Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
title_full_unstemmed	Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
title_sort	identification of immune-related gene signatures in lung adenocarcinoma and lung squamous cell carcinoma
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/5043de7eff614eebada5e7504d27f9b1
work_keys_str_mv	AT nali identificationofimmunerelatedgenesignaturesinlungadenocarcinomaandlungsquamouscellcarcinoma AT nali identificationofimmunerelatedgenesignaturesinlungadenocarcinomaandlungsquamouscellcarcinoma AT jiahongwang identificationofimmunerelatedgenesignaturesinlungadenocarcinomaandlungsquamouscellcarcinoma AT xianquanzhan identificationofimmunerelatedgenesignaturesinlungadenocarcinomaandlungsquamouscellcarcinoma AT xianquanzhan identificationofimmunerelatedgenesignaturesinlungadenocarcinomaandlungsquamouscellcarcinoma AT xianquanzhan identificationofimmunerelatedgenesignaturesinlungadenocarcinomaandlungsquamouscellcarcinoma
_version_	1718406620276326400

Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Ejemplares similares